Lefamulin, sold under the brand name Xenleta, is an antibiotic medication used it to treat adults with community-acquired bacterial pneumonia.

[5][6][7] Relatively common side effects include diarrhea, nausea, pain at the site of injection, and liver inflammation.

[9][10] Lefamulin was approved for medical use in the United States in August 2019,[5][11] and in the European Union in July 2020.

[12] Lefamulin has in vitro activity against Streptococcus pneumoniae, viridans group Streptococci, Moraxella catarrhalis, Enterococcus faecium, methicillin-resistant Staphylococcus aureus (MRSA), among other bacteria.

Although pleuromutilin antibiotics were first developed in the 1950s, lefamulin is the first to be used for systemic treatment of bacterial infections in humans.